<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00150891</url>
  </required_header>
  <id_info>
    <org_study_id>NTx-prosp-001</org_study_id>
    <nct_id>NCT00150891</nct_id>
  </id_info>
  <brief_title>Th1, Th2 and Monokine Responses as Risk Factors of Renal Transplant Rejection</brief_title>
  <official_title>Role of Th1, Th2 and Monokine Responses as Risk Factors of Acute and Chronic Renal Transplant Rejection – Impact of Different Immunosuppressive Protocols</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fresenius AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biotest</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Giessen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic transplant rejection remains the main cause of late kidney graft loss. We showed
      previously that patients with pretransplant CD4 helper defects and low in-vitro IL-10
      responses demonstrated an extremely low risk of acute rejection and a significantly better 1-
      and 3-year graft function whereas pretransplant Th1 responses were not predictive (Weimer R
      et al. 1996 and 1998). In liver transplant recipients, we found CD4 helper function and
      in-vitro IL-10 responses significantly decreased compared to CsA-treated patients (Zipperle
      et al. 1997). If the same effect will be demonstrated in renal transplant recipients,
      Tacrolimus (Tacr) treatment might result in enhanced graft survival compared to CsA, when CD4
      helper function and in-vitro IL-10 responses of the individual patient are elevated. Other
      studies of our group suggest a beneficial role of enhanced T-suppressor activity and of an
      IL-6 independent B cell/monocyte defect in the maintenance of long-term stable graft
      function, whereas enhanced monokine secretion (TNF-a, GM-CSF, IL-6) was found in chronic
      rejection (Weimer et al. 1990, 1992, 1994, 1998).

      In the current randomized prospective study we will analyze the impact of CsA versus Tacr and
      of MMF versus azathioprine on Th1, Th2 and monokine responses and their predictive value
      regarding occurrence of acute and chronic rejection. With a proposed follow-up of 5 years
      this study might enable a patient-tailored immunosuppressive therapy resulting in prolonged
      graft survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic transplant rejection remains the main cause of late kidney graft loss. We showed
      previously that patients with pretransplant CD4 helper defects and low in-vitro IL-10
      responses demonstrated an extremely low risk of acute rejection and a significantly better 1-
      and 3-year graft function whereas pretransplant Th1 responses were not predictive (Weimer R
      et al. 1996 and 1998). In liver transplant recipients, we found CD4 helper function and
      in-vitro IL-10 responses significantly decreased compared to CsA-treated patients (Zipperle
      et al. 1997). If the same effect will be demonstrated in renal transplant recipients,
      Tacrolimus (Tacr) treatment might result in enhanced graft survival compared to CsA, when CD4
      helper function and in-vitro IL-10 responses of the individual patient are elevated. Other
      studies of our group suggest a beneficial role of enhanced T-suppressor activity and of an
      IL-6 independent B cell/monocyte defect in the maintenance of long-term stable graft
      function, whereas enhanced monokine secretion (TNF-a, GM-CSF, IL-6) was found in chronic
      rejection (Weimer et al. 1990, 1992, 1994, 1998).

      In the current randomized prospective study we will analyze the impact of CsA versus Tacr and
      of MMF versus azathioprine (Aza; 3 treatment groups: CsA/Aza, CsA/MMF and Tacr/Aza; steroid
      and prophylactic ATG treatment according to the Giessen protocol) on immune parameters and
      their predictive value regarding occurrence of acute and chronic rejection. As immune
      parameters we will assess CD4 helper function, in-vitro IL-4 and IL-10 responses of T cells
      and CD4+ T cells, respectively, in allogeneic cocultures of patient T cells with control B
      cells and in PHA-stimulated T cell cultures, T-cell dependent (PWM-stimulated allogeneic
      cocultures) and T-independent (SAC I-stimulated B cell cultures) immunoglobulin-secreting
      cell (ISC) responses, B-cell IL-6 and IL-10 responses and monokine responses (LPS-stimulated
      monocyte cultures) pretransplant, and 4 months, 1 year, 2 years and 5 years posttransplant.
      Serum cytokines and easily measurable parameters as neopterin, sIL-1RA and sCD30 will be
      assessed at the same time points. The same is true for flow cytometric analysis of cytokine
      receptor, adhesion molecule, costimulator molecule and surface molecule expression,
      respectively, which play an important role in cell-cell interactions and tolerance induction.
      Cytokine promoter gene polymorphisms will be determined to potentially enable pretransplant
      risk estimation. To establish a broadly available and rapid diagnostic method, we will
      compare the data of intracellular cytokine testing with the results of the much more
      difficult and time consuming coculture analyses used in our previous studies.

      With a proposed follow-up of 5 years this prospective randomized study might enable a
      patient-tailored immunosuppressive therapy resulting in better graft function and prolonged
      graft survival by preventing chronic allograft rejection.

      Weimer R, Pomer S, Staehler G, Opelz G. Increased T suppressor activity in renal transplant
      recipients with long-term stable graft function. Clinical Transplantation 1990; 4: 280-286

      Weimer R, Zipperle S, Daniel V, Pomer S, Staehler G, Opelz G. In vitro B cell response in
      long-term renal transplant recipients. Transplant Proc 1992; 24(6): 2537-2538

      Weimer R, Zipperle S, Daniel V, Pomer S, Staehler G, Opelz G. IL-6 independent monocyte/B
      cell defect in renal transplant recipients with long-term stable graft function.
      Transplantation 1994; 57(1): 54-59

      Weimer R, Zipperle S, Daniel V, Carl S, Staehler G, Opelz G. Pretransplant CD4 helper
      function and IL-10 response predict risk of acute kidney graft rejection. Transplantation
      1996; 62(11): 1606-1614

      Zipperle S, Weimer R, Golling M, Daniel V, Otto G, Opelz G. Impaired T cell IL-10 secretion
      and CD4 helper function in liver transplant patients treated with tacrolimus. Transplant Proc
      1997; 29(1-2): 1079-1080

      Weimer R, Zipperle S, Daniel V, Carl S, Staehler G, Opelz G. Superior 3-year kidney graft
      function in patients with impaired pretransplant Th2 responses. Transplant Int 1998; 11
      (Suppl 1): 350-356
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1998</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Screening</primary_purpose>
    <observational_model>Defined Population</observational_model>
    <time_perspective>Longitudinal, Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">84</enrollment>
  <condition>Renal Failure, Chronic</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Kidney transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine A</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azathioprine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Renal transplant recipients in the Giessen renal transplant unit

        Exclusion Criteria:

          -  Contraindications against blood-taking (anemia with hemoglobin&lt;9.5 g/l, hypotension
             etc.)

          -  No informed consent by the patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rolf Weimer, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, University of Giessen, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Internal Medicine, University of Giessen</name>
      <address>
        <city>Giessen</city>
        <zip>D-35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Weimer R, Mytilineos J, Feustel A, Preiss A, Daniel V, Grimm H, Wiesel M, Opelz G. Mycophenolate mofetil-based immunosuppression and cytokine genotypes: effects on monokine secretion and antigen presentation in long-term renal transplant recipients. Transplantation. 2003 Jun 27;75(12):2090-9.</citation>
    <PMID>12829918</PMID>
  </reference>
  <reference>
    <citation>Weimer R, Melk A, Daniel V, Friemann S, Padberg W, Opelz G. Switch from cyclosporine A to tacrolimus in renal transplant recipients: impact on Th1, Th2, and monokine responses. Hum Immunol. 2000 Sep;61(9):884-97.</citation>
    <PMID>11053632</PMID>
  </reference>
  <reference>
    <citation>Weimer R, Zipperle S, Daniel V, Carl S, Staehler G, Opelz G. Superior 3-year kidney graft function in patients with impaired pretransplant Th2 responses. Transpl Int. 1998;11 Suppl 1:S350-6.</citation>
    <PMID>9665014</PMID>
  </reference>
  <reference>
    <citation>Zipperle S, Weimer R, Golling M, Daniel V, Otto G, Opelz G. Impaired T-cell IL-10 secretion and CD4 helper function in liver transplant patients treated with tacrolimus. Transplant Proc. 1997 Feb-Mar;29(1-2):1079-80.</citation>
    <PMID>9123208</PMID>
  </reference>
  <reference>
    <citation>Weimer R, Zipperle S, Daniel V, Carl S, Staehler G, Opelz G. Pretransplant CD4 helper function and interleukin 10 response predict risk of acute kidney graft rejection. Transplantation. 1996 Dec 15;62(11):1606-14.</citation>
    <PMID>8970616</PMID>
  </reference>
  <reference>
    <citation>Weimer R, Zipperle S, Daniel V, Pomer S, Staehler G, Opelz G. IL-6 independent monocyte/B cell defect in renal transplant recipients with long-term stable graft function. Transplantation. 1994 Jan;57(1):54-9.</citation>
    <PMID>7507271</PMID>
  </reference>
  <results_reference>
    <citation>Weimer R, Streller S, Staak A, Heilke M, Li D, Dietrich H, Daniel V, Feustel A, Rainer L, Zinn S, Friemann S, Ernst W, Grimm H, Padberg W, Zimmermann T, Opelz G. Effects of three immunosuppressive regimens on CD4 helper function, B cell monocyte and cytokine responses in renal transplant recipients: 4-month follow-up of a prospective randomized study. Transplant Proc. 2002 Sep;34(6):2377-8.</citation>
    <PMID>12270445</PMID>
  </results_reference>
  <results_reference>
    <citation>Weimer R, Staak A, Süsal C, Streller S, Yildiz S, Pelzl S, Renner F, Dietrich H, Daniel V, Rainer L, Kamali-Ernst S, Ernst W, Padberg W, Opelz G. ATG induction therapy: long-term effects on Th1 but not on Th2 responses. Transpl Int. 2005 Feb;18(2):226-36.</citation>
    <PMID>15691277</PMID>
  </results_reference>
  <results_reference>
    <citation>Weimer R, Süsal C, Yildiz S, Streller S, Pelzl S, Staak A, Renner F, Dietrich H, Daniel V, Feuring E, Kamali-Ernst S, Ernst W, Padberg W, Opelz G. sCD30 and neopterin as risk factors of chronic renal transplant rejection: impact of cyclosporine A, tacrolimus, and mycophenolate mofetil. Transplant Proc. 2005 May;37(4):1776-8.</citation>
    <PMID>15919463</PMID>
  </results_reference>
  <results_reference>
    <citation>Weimer R, Süsal C, Yildiz S, Staak A, Pelzl S, Renner F, Dietrich H, Daniel V, Kamali-Ernst S, Ernst W, Padberg W, Opelz G. Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens. Am J Transplant. 2006 Aug;6(8):1865-74. Epub 2006 Jun 9.</citation>
    <PMID>16771810</PMID>
  </results_reference>
  <verification_date>May 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>May 8, 2007</last_update_submitted>
  <last_update_submitted_qc>May 8, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2007</last_update_posted>
  <keyword>Th1</keyword>
  <keyword>Th2</keyword>
  <keyword>B cell</keyword>
  <keyword>monokines</keyword>
  <keyword>kidney transplantation</keyword>
  <keyword>acute rejection</keyword>
  <keyword>chronic rejection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

